Leeds Teaching Hospitals NHS Trust

Running trials

• Recruiting

  Physical Activity Promotion and Clinical Remission in Severe Asthma

  NCT07735494· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  Controlling Hyperactive Immunity With Long-lived Lymphocytes

  NCT07473154· Phase 1/2· Source

• Not yet recruiting

  Digoxin and Senolysis in Heart Failure and Diabetes Mellitus

  NCT06240403· Phase 2· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Source

• Recruiting

  A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

  NCT07284121· Source

• Active, not recruiting

  A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06736990· Phase 2· Source

• Recruiting

  Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences

  NCT06774014· Source

• Recruiting

  A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

  NCT06810505· Phase 3· Source

• Active, not recruiting

  REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

  NCT06557798· Source

• Recruiting

  Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

  NCT06769633· Phase 2· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Source

• Not yet recruiting

  The U.K. NorthStar Clinical Network

  NCT06711692· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· Source

• Recruiting

  Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart

  NCT06505798· Source

• Active, not recruiting

  A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy

  NCT06713135· Phase 4· Source

• Recruiting

  A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

  NCT06547840· Phase 1· Source

• Recruiting

  The Force Frequency Relationship in Heart Failure and Diabetes Mellitus: a Metabolic Aetiology?

  NCT07309523· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

  NCT06486441· Phase 3· Source

• Recruiting

  Assessing NHS ImplemeNTation of an onlinE Resilience Training Acceptance and Commitment Therapy (ACT) Programme to Prevent Job Loss in Multiple Sclerosis

  NCT06728956· Source

• Active, not recruiting

  Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06158841· Phase 3· Source

• Active, not recruiting

  Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

  NCT06230354· Phase 2· Source

• Recruiting

  Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial

  NCT06355583· Phase 2· Source

• Recruiting

  An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

  NCT06435000· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Source

• Active, not recruiting

  MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06132256· Phase 2· Source

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· Source

• Recruiting

  Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

  NCT05848765· Phase 2· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Source

• Active, not recruiting

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

  NCT05618028· Phase 1· Source

• Recruiting

  DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution

  NCT05389774· Source

• Recruiting

  A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

  NCT05744921· Phase 3· Source

• Active, not recruiting

  DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

  NCT05566795· Phase 3· Source

• Active, not recruiting

  Registry on Percutaneous Electrochemotherapy

  NCT05267080· Source

• Recruiting

  ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

  NCT05580562· Phase 3· Source

• Recruiting

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· Phase 3· Source

• Recruiting

  UK Heart Failure With Preserved Ejection Fraction

  NCT05441839· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

  NCT05409066· Phase 3· Source

• Recruiting

  A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

  NCT05613023· Phase 3· Source

• Active, not recruiting

  Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

  NCT05524883· Phase 1/2· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382286· Phase 3· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· Phase 3· Source

• Active, not recruiting

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· Phase 3· Source

• Recruiting

  A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT05085028· Phase 3· Source

• Recruiting

  Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

  NCT04895436· Phase 2· Source

• Active, not recruiting

  A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  NCT05100862· Phase 3· Source

• Active, not recruiting

  COVID-19 Antibody Responses In Cystic Fibrosis

  NCT04863573· Source

• Recruiting

  (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  NCT04996875· Phase 2· Source

• Recruiting

  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

  NCT05065216· Phase 2/3· Source

• Active, not recruiting

  A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure4 recruiting
• Childhood cancers3 recruiting
• Lung cancer3 recruiting
• Acute myeloid leukemia2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Follicular lymphoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Myelodysplastic syndromes2 recruiting
• Type 2 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Migraine1 recruiting
• Multiple sclerosis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

  NCT06532032· Phase 1/2· Source

• Completed

  Cue X as a Treatment for People With Parkinson's Disease

  NCT05794542· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· Source

• Completed

  Evaluation of the MiniMed 780 System in Paediatric Subjects

  NCT05574062· Source

• Completed

  The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy

  NCT05432232· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Completed

  Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

  NCT05156320· Phase 3· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· Phase 3· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· Source

• Terminated

  Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

  NCT04632940· Phase 3· Source

• Completed

  PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

  NCT04870333· Phase 2/3· Source

• Completed

  A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

  NCT03992430· Phase 3· Source

• Completed

  CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)

  NCT04226248· Phase 3· Source

• Completed

  Limitations of Aerobic Capacity in Chronic Heart Failure

  NCT04332536· Source

• Completed

  The MOCA I Study - Microvascular Obstruction with CoFI™ System Assessment

  NCT03654573· Phase 1· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Source

• Completed

  WORKWELL: Testing Work Advice for People With Arthritis

  NCT03942783· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Source

• Completed

  A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

  NCT03631784· Phase 2· Source

• Completed

  Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

  NCT03644303· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Source

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· Source

• Completed

  Long-term Follow-up Gene Therapy Study for RPGR- XLRP

  NCT04312672· Source

• Completed

  Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

  NCT02947347· Phase 3· Source

• Completed

  Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT02500381· Phase 3· Source

• Completed

  Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

  NCT02461888· Phase 2· Source

• Completed

  PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

  NCT02423603· Phase 2· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· Source

Trial sites

• Leeds Teaching Hospital NHS Trust4 trials
• Leeds Teaching Hospitals NHS Trust67 trials
• Leeds Teaching Hospitals NHS Trust /ID# 1575501 trial
• Leeds Teaching Hospitals NHS Trust /ID# 1579491 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2011061 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2304711 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2454701 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2462411 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2507321 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2604661 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2611011 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2734491 trial
• Leeds Teaching Hospitals NHS Trust /ID# 2794171 trial
• Leeds Teaching Hospitals NHS Trust (Site 0751)1 trial
• Leeds Teaching Hospitals NHS Trust (Site 1050)1 trial
• Leeds Teaching Hospitals NHS Trust (Site 1209)1 trial
• Leeds Teaching Hospitals NHS Trust (Site 1401)1 trial
• LEEDS TEACHING HOSPITALS NHS TRUST - St James1 trial
• Leeds Teaching Hospitals NHS Trust - St. James Institute of Oncology1 trial
• Leeds Teaching Hospitals NHS Trust, st James's Institute of Oncology1 trial
• Leeds Teaching Hosp NHS Trust1 trial
• The Leeds Teaching Hospitals NHS Trust9 trials
• The Leeds Teaching Hospitals NHS Trust, Leeds General Infimary1 trial
• Leeds Teaching Hospitals NHS Trust1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Systemic sclerosis (scleroderma)34 works · 1 trials
• Rheumatoid arthritis30 works · 2 trials
• Psoriasis25 works · 1 trials
• Psoriatic arthritis21 works · 1 trials
• Ankylosing spondylitis11 works · 0 trials
• Chronic lymphocytic leukaemia7 works · 4 trials